Fosgonimeton - ALZFORUM Background NDX-1017 is a brain-penetrant small molecule that activates signaling via the hepatocyte growth factor (HGF) MET receptor system (Moebius and Church, 2023) HGF promotes proliferation and survival of neurons, enhances hippocampal synaptic plasticity, and boosts learning and memory (Akimoto et al , 2004; Kato et al , 2012) NDX-1017 is being developed as a subcutaneous once-daily
Traumatic brain injury and cognitive change over 30 years among . . . Schneider AL, Pike JR, Elser H, Coresh J, Mosley TH, Diaz-Arrastia R, Gottesman RF Traumatic brain injury and cognitive change over 30 years among community-dwelling older adults Alzheimers Dement 2024 Jul 5; PubMed Recommends Please login to recommend the paper
The prevalence and progression of mild cognitive impairment among . . . Hu C, Yu D, Sun X, Zhang M, Wang L, Qin H The prevalence and progression of mild cognitive impairment among clinic and community populations: a systematic review and meta-analysis Int Psychogeriatr 2017 Oct;29 (10):1595-1608 PubMed
Demonstrated brain insulin resistance in Alzheimers disease patients . . . Type 2 diabetes has been identified as one of the risk factors for AD Two papers analyzing insulin signaling in the brains of Alzheimer’s disease (AD) patients have been published back to back in the Journal for Clinical Investigation
QALSODY™ - ALZFORUM Background This drug is a second-generation antisense oligonucleotide (ASO) targeting the mRNA for superoxide dismutase 1 It mediates mRNA degradation to prevent SOD1 protein synthesis and reduce levels of SOD1 protein Tofersen is being developed for ALS caused by SOD1 mutations, which account for about 20 percent of all familial ALS and 2 percent of all ALS cases Although the exact
Ulefnersen - ALZFORUM Background ION363 is an antisense oligonucleotide designed to reduce the production of a mutated, neurotoxic form of the Fused in Sarcoma (FUS) protein FUS mutations have been identified as a cause of familial ALS and frontotemporal lobar degeneration ION363 is delivered by intrathecal injection
TPM (Thy-1 PS1. M146V) | ALZFORUM Brain Res 2004 Aug 13;1017 (1-2):130-6 PubMed Sasmita AO, Ong EC, Nazarenko T, Mao S, Komarek L, Thalmann M, Hantakova V, Spieth L, Berghoff SA, Barr HJ, Hingerl M, Börensen F, Hirrlinger J, Simons M, Stevens B, Depp C, Nave KA Parental origin of transgene modulates amyloid-β plaque burden in the 5xFAD mouse model of Alzheimer's disease
GRANTS - ALZFORUM You searched national-alzheimers-coordinating-center-u24-clinical-trial-not-allowed-rfa-ag-26-003